JPMorgan analyst Anupam Rama initiated coverage of Cidara Therapeutics (CDTX) with an Overweight rating and $200 price target The firm says the Phase 2b NAVIGATE study of Cidara’s lead asset, CD388, for influenza show the “game-changing potential of the product.” In addition, the addressable population being assessed in the ongoing Phase 3 ANCHOR study is wider than many expected, the analyst tells investors in a research note. JPMorgan is at the higher end of Street estimates for probability-of-success and peak sales for CD388. It assumes peak sales of $4B in the U.S. alone with a 75% probability of success.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CDTX:
- Cidara Therapeutics price target raised to $150 from $110 at H.C. Wainwright
- Cidara Therapeutics: Strategic Advancements and Financial Strength Bolster Buy Rating
- Cidara Therapeutics: Strong Buy Rating Backed by Breakthrough Therapy Designation and Promising CD388 Efficacy
- Cidara Therapeutics receives U.S. FDA BTD for CD388
- Cidara Therapeutics price target raised to $173 from $153 at Citizens JMP